| Theme | Acute Liver Injury ： Drug-induced and Viral Liver Injuries | |
|---|---|---|
| Title | Treatment for Drug-induced Liver Injury | |
| Publish Date | 2010/10 | |
| Author | Yasushi Matsuzaki | Department of Gastroenterology and Hepatology, Tokyo Medical University Ibaraki Medical Center |
| Author | Tadashi Ikegami | Department of Gastroenterology and Hepatology, Tokyo Medical University Ibaraki Medical Center |
| [ Summary ] | Regarding treatment for drug-induced liver injury, the most important aspect is early recognition and discontinuation of the presumed causative agent. In Japan, ursodeoxycholic acid (UDCA) and glycyrrhizin (SNMC) are used for the drug-induced hepatotoxicity and cholestasis. UDCA is safe and well tolerated. At the same time, a short course of corticosteroid treatment is used for prolonged drug-induced cholestasis. Recently, it has been found that the efficacy of some agents for patients with drug-induced liver injury has an interpatient's variability due to the particular of individual pharmacogenomics. If the functional basis for such efficacy can be established, a firmer conceptual basis or more appropriate pharmacologic agents to obtain clinical resolution may be established. | |